Van Spall, Harriette G. C. http://orcid.org/0000-0002-8370-4569
Bastien, Arnaud
Gersh, Bernard http://orcid.org/0000-0001-5605-900X
Greenberg, Barry
Mohebi, Reza
Min, James
Strauss, Karsten
Thirstrup, Steffen http://orcid.org/0000-0003-0903-682X
Zannad, Faiez http://orcid.org/0000-0001-7456-1570
Funding for this research was provided by:
CVCT meetings are supported by unrestricted educational grants with no allocation for speakers’ fees.
Article History
Received: 28 September 2023
Accepted: 22 December 2023
First Online: 15 February 2024
Competing interests
: H.G.C.V.S. reports grants from the Canadian Institutes of Health Research and the Heart and Stroke Foundation. A.B. reports employment, travel and/or meeting attendance support, and stock or stock options from Bristol Myers Squibb; and membership on the Board of Trustees (unpaid) for Coriell Medical Research Institute. J.M. reports participation on a medical advisory board for Arineta; employment (CEO) with Cleerly; and an equity interest in Cleerly. K.S. reports employment, travel and/or meeting attendance support, and stock or stock options from Olink Proteomics. F.Z. reports consulting fees from 89bio, Applied Therapeutics, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardior Pharmaceuticals, Cellprothera, Cereno Scientific, CEVA, CVRx, Merck, Novartis, NovoNordisk, Owkin, Pfizer and Servier; honoraria for lectures from Bayer, Boehringer Ingelheim, CEVA, CVRx, Merck and Novartis; fees for participation on a data safety monitoring board or advisory board from Acceleron/Merck; and equity interests in G3 Pharmaceuticals, Cereno Pharmaceuticals, Cardiorenal, Eshmoun Clinical Research and CVCT. The other authors declare no competing interests. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agency/agencies or organizations with which the authors are employed or affiliated.